The efficacy of two electron transport inhibitors (720C80 and 993C76) on murine strongyloidiasis: a comparison with albendazole.
The clinical efficacy of albendazole (ABZ) in the treatment of chronic uncomplicated strongyloidiasis has been reported to be highly variable. In our murine model of strongyloidiasis a single oral dose of 5 and 10 mg kg-1 ABZ reduced (at day 4 post infection) the faecal larval count (FLC) by 54.2 +/- 12.5% and 81.5 +/- 10.2%, respectively. 100 mg kg-1 ABZ reduced the FLC by 100%. Two inhibitors of protozoan and filarial electron transport (720C80 and 993C76) inhibited the endogenous O2 consumption of intact infective (L3) larvae of S. ratti by > 50% at 2 x 10(-5) M in vitro, and reduced the FLC by 72 +/- 9.3% and 62.0 +/- 10.3% respectively in vivo, at a dose of 70 mg kg-1. These results suggest that compounds designed as selective inhibitors of protozoan electron transport have significant efficacy against murine strongyloidiasis and may prove useful in the management of human strongyloidiasis.
Armson
A
A
School of Biomedical Sciences, Curtin University of Technology, Perth, Western Australia.
Thompson
R C
RC
Reynoldson
J A
JA
Grubb
W B
WB
Mendis
A H
AH
D015766:Albendazole / Q000627:therapeutic use*; D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D005260:Female; D009285:Naphthoquinones / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013322:Strongyloidiasis / Q000188:drug therapy*
D000981:Antiprotozoal Agents; D009285:Naphthoquinones; C046326:buparvaquone; C028032:parvaquone; D015766:Albendazole